Pancreatitis During Treatment with Liraglutide
DOI:
https://doi.org/10.6092/1590-8577/1107Keywords:
Incretins, liraglutide, PancreatitisAbstract
No abstract available.
Image: San Camillo Hospital. Rome, Italy
Downloads
References
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-45. [PMID 7249508]
Pinelli NR, Hurren KM. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother 2011; 45:850-60. [PMID 21730278]
Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32:834-8. [PMID 19208917]
Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide. The FDA’s review of a new antidiabetic therapy. N Engl J Med 2010; 362:774-7. [PMID 20164475]
Knezevich E, Crnic T, Kershaw S, et al. Liraglutide-associated acute pancreatitis. Am J Health Syst Pharm 2012; 69:386-9. [PMID 22345417]
Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother 2011; 45:e22. [PMID 21487080]
Koehler JA, Baggio LL, Lamont BJ, et al. Glucagon-like peptide-1- receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009; 58:2148-61. [PMID 19509017]
Nyborg NC, Mølck AM, Madsen LW, et al. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012; 61:1243-9. [PMID 22338093]
